11 July 2025 | 9:40AM CST China Healthcare: Jun 2025 China hospital equipment bidding: Growth on hold as ASP pressure unfolds, less expectation from stimulus in 2H We continue to track the procurement value of the main medical devices in China. Although the June bidding value data maintained a YoY growth rate of 49%, it still came in below our previous expectations due to a 3% MoM decline. We believe the decline was primarily driven by lower unit prices as a result of VBPs - continuing the trend observed in ...

将投中网设为"星标⭐"，第一时间收获最新推送 这些BP的曝光到底会给项目带来什么样的影响？ 作者丨 蒲凡 来源丨 投中网 今天的话题，要从今年大火的 AI Agent 产品 Manus 聊起。 自从今年 3 月顺利接棒 Deepseek 带来的全民狂热，关于 Manus 母公司 " 蝴蝶效应 " 拿到融资的消息一直都没有中断过。在这些传闻组成的世界线 里， Manus 的融资目标从最初的 5000 万美元一路上涨到 1 亿美元，头部机构们排队问价，估值也一路攀升到了 15 亿美元以上。最新的消息出现 在 5 月，有人说 Manus 远赴海外寻求机会，找到了 1 亿美元，投资方是著名的 Bencnmark 。 当然，这些传闻都没有得到过蝴蝶效应的正式确认。舆论也没有表现得过于惊讶：毕竟当下的一级市场，还能看得到 β 的赛道已经不多了，这种带有强 烈共识的项目必然会受到追捧。 但最近，事情似乎往奇怪的方向发展。我的同事意外结识了一位投资人，声称表示自己正在帮助 MANUS 融资，目前已经十分接近敲定。为了证明自己 所言非虚，该投资人向我们展示了两份 BP ， 据说一份是面向美元基金的，另一份是面向人民币基金的 。 ...

Core Viewpoint - Johnson & Johnson's MedTech segment, which constitutes approximately 36% of total revenues, is experiencing growth driven by newly acquired cardiovascular businesses and new product uptake, but faces challenges in the Asia Pacific region, particularly in China due to government procurement programs and competitive pressures [1][2][4]. Group 1: MedTech Segment Performance - The MedTech segment's growth in Q2 is attributed to the acquisition of Abiomed and Shockwave, alongside the continued uptake of new products [2]. - Sales in China are negatively impacted by the volume-based procurement (VBP) program and an anticorruption campaign, with no expected improvement in 2025 [2]. - Competitive pressures are affecting growth in specific MedTech areas, such as PFA ablation catheters in U.S. electrophysiology [3]. Group 2: Future Outlook - Sales are anticipated to be higher in the second half of 2025 compared to the first half as the business overcomes challenging first-quarter comparisons and new products gain traction [4]. - Tariff-related costs are expected to negatively impact profits in the MedTech segment [4]. Group 3: Competitive Landscape - J&J's MedTech unit faces significant competition from major players like Medtronic, Abbott, Stryker, and Boston Scientific, each specializing in various medical technologies [4][5]. Group 4: Financial Performance and Valuation - J&J's shares have outperformed the industry with a year-to-date increase of 9.7%, compared to a 0.6% rise in the industry [6]. - The company's shares are reasonably priced, trading at a price/earnings ratio of 14.43, lower than the industry average of 14.99 and below its five-year mean of 15.73 [8]. - The Zacks Consensus Estimate for 2025 earnings has increased slightly from $10.60 to $10.62 per share over the past 30 days [10].

沪镍不锈钢市场周报 供需两弱政策利好 镍不锈钢震荡偏强 瑞达期货研究院 「2025.07.04」 研究员： 王福辉 期货从业资格号F03123381 期货投资咨询从业证书号Z0019878 获取更多资讯 业 务 咨 询 添 加 客 服 关 注 我 们 目录 1、周度要点小结 2、期现市场 3、产业情况 「 周度要点小结」 来源：瑞达期货研究院 3 周度回顾：本周沪镍主力震荡上涨，周线涨跌幅为+1.86%，振幅3.66%。截止本周主力合约收盘报价120480元/吨。 行情展望：宏观面，美国6月非农新增就业14.7万人超预期，4、5月合计上修1.6万人，失业率意外降至4.1%。美 国6月ISM服务业PMI指数50.8，就业指数收缩，商业活动和订单回升。美联储降息预期大降。基本面，印尼政府 PNBP政策发放限制，提高镍资源供应成本，内贸矿升水持稳运行；菲律宾镍矿供应回升，不过国内镍矿港库下降， 原料呈现偏紧局面。冶炼端，目前原料价格较高，而镍价处于下行趋势，对其余冶炼厂造成利润亏损的影响，部 分非一体化冶炼厂选择减产。需求端，不锈钢厂利润压缩，300系进行减产；新能源汽车需求继续爬升，但占比 较小影响有限。近期供需 ...

更多资料加入知识星球：水木调研纪要 关注公众号：水木Alpha 29 June 2025 | 3:25PM HKT China Resources Pharmaceuticals (3320.HK): China Healthcare Corporate Day 2025 — Key Takeaways: Soft growth in 1H amid Presenter: Yulin Chen - Head of Investor Relations Bottom line: Management noted soft growth in 1H due to challenging industry environment and toned down previous guidance of double-digit y/y sales growth for 2025 pending recovery situation in 2H. Cash collection remained under pressure. Key Takeaways Soft growth in 1H: management to ...

免责声明 本报告中的信息均来源于公开可获得资料，瑞达期货股份有限公司力求准确可靠，但对这些信息的准确性及完整性不做任 不锈钢产业日报 2025-06-30 | 项目类别 | 数据指标 | 最新 | 环比 数据指标 | 最新 | 环比 | | --- | --- | --- | --- | --- | --- | | 期货市场 | 期货主力合约收盘价:不锈钢(日,元/吨) | 12610 | -10 08-09月合约价差:不锈钢(日,元/吨) | 45 | 0 | | | 期货前20名持仓:净买单量:不锈钢(日,手) | -6997 | -464 主力合约持仓量:不锈钢(日,手) | 101013 | -6160 | | | 仓单数量:不锈钢(日,吨) | 112140 | -187 | | | | 现货市场 | 304/2B卷:切边:无锡(日,元/吨) | 13400 | 0 市场价:废不锈钢304:无锡(日,元/吨) | 9100 | 0 | | | SS主力合约基差(日,元/吨) | 300 | 65 | | | | 上游情况 | 电解镍产量(月,吨) | 29430 | 1120 镍铁产量合计(月,万金 ...

金融工程 | 金工定期报告 金融工程 证券研究报告 因子跟踪周报：小市值、Beta 因子表现较好- 20250628 因子 IC 跟踪 IC 方面，最近一周，小市值、Beta、1 月特异度等因子表现较好，bp 三 年分位数、股息率、季度 ep 等因子表现较差；最近一月，1 月特异度、 小市值、Beta 等因子表现较好，前五大股东持股比例合计、一致预期 EPS 变动、一年动量等因子表现较差；最近一年，小市值、1 个月反转、 Fama-French 三因子 1 月残差波动率等因子表现较好，一年动量、季度 roe、季度 roa 等因子表现较差。 因子多头组合跟踪 多头组合方面，最近一周，Beta、小市值、业绩预告精确度等因子表现较 好，财报超研报预期程度、基于一致预期的标准化预期外盈利、90 天内 预期调整均值等因子表现较差；最近一月，Beta、小市值、1 月特异度等 因子表现较好，基于一致预期的标准化预期外盈利、bp 三年分位数、1 个月非流动性冲击等因子表现较差；最近一年，小市值、1 个月换手率波 动、1 个月日均换手率等因子表现较好，90 天内预期调整均值、基于一致 预期的标准化预期外盈利、90 天净上调预期 ...

I've never seen him like this. Um, he's still wearing the same clothes that they got him in. Um, he still has blood on his shirt um, from the beating. His eyes are still burning. He hasn't been able to shower. He hasn't been able to wash his face. Um, he says he's in a in a in a cage, you can say, um, with at least 70 other people. No privacy. um one toilet. Uh he's received water maybe once a day and very very little food. That you may remember was Alejandro Barco, the US Marine veteran whose father Narcis ...

Key Takeaways JNJ's MedTech sales rose 4.1% in Q1 2025, driven by new products and recent acquisitions. Headwinds in China from VBP and anticorruption efforts are expected to persist through 2025. Stronger second-half 2025 sales expected as comps ease and product momentum builds up across segments.Johnson & Johnson (JNJ) is one of the few large drug and medical device companies with a presence in both the pharmaceuticals as well as medical devices segments. J&J’s medical devices segment, called MedTech, o ...

We hosted Shandong Weigao's CFO and IR team with investors on June 25 at our China Healthcare Corporate Day 2025. Bottom line: Mmgt noted 1) its full-year revenue growth guidance of 10–15% y/y remains unchanged. 1H25 may exhibit slower momentum, while management remains confident in a stronger 2H rebound due to a more favorable base (1H/2H24 revenue split at Rmb6.64bn/6.45bn) and accelerated new product contribution. 2) The ramp-up of new products is progressing as planned, particularly in perioperative car ...